Canakinumab as effective therapy in anakinra‐refractory Schnitzler syndrome: a case‐based review

Internal Medicine Journal 2026

View at publisher
Authors: Sergio de Santos Belinchón, Cristina Ausín García, Pablo Daniel Lorenzo Barcia, Tatiana Paula Pire García, Héctor Balastegui, Cecilia Muñoz Delgado, María Victoria Villalba García, Cristina Lavilla Olleros
DOI: 10.1111/imj.70233
Cited by: 0
References: 14

Abstract

Schnitzler syndrome is a rare autoinflammatory syndrome caused by a dysregulation of the interleukin-1β signalling pathway. Symptoms tend to appear in middle age and include urticariform skin lesions, fever, bone pain, lymphadenopathy and IgM monoclonal gammopathy. Interleukin-1 (IL-1) targeted therapy constitutes the basis for treatment and can lead to complete resolution of symptoms. We report a case of Schnitzler syndrome in a 49-year-old man refractory to anakinra and subsequently treated successfully with canakinumab.

Fields of Study & Subjects

Inflammasome and immune disorders Autoimmune and Inflammatory Disorders Research Immunodeficiency and Autoimmune Disorders

Publication details

Journal / source
Internal Medicine Journal
Volume
56
Issue
2
Pages
306–310
Publication date
1 February 2026
Language
EN